Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in JAK2-mutated Myeloproliferative Neoplasms
NCT02311569Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirabegron in myeloproliferative neoplasms (MPN), sponsored by Swiss Group for Clinical Cancer Research. Started Apr 2015; status: completed.
02
Drugs
mirabegron
03
Conditions
myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT02311569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311569.